查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990069

動物模型市場：依動物種類、模型類型、應用和最終用戶分類－2026-2032年全球市場預測

Animal Model Market by Animal Type, Model Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物模型市場價值將達到 34.2 億美元，到 2026 年將成長到 36.8 億美元，到 2032 年將達到 59.8 億美元，複合年成長率為 8.27%。

主要市場統計數據
基準年 2025 34.2億美元
預計年份：2026年 36.8億美元
預測年份 2032 59.8億美元
複合年成長率 (%) 8.27%

全面介紹科學進步、倫理要求和監管期望如何交織並重新定義臨床前動物模型策略。

現代動物模型環境正處於快速科學創新、嚴格的倫理要求和不斷發展的法律規範三者交匯的十字路口。臨床前研究人員和機構領導者必須應對日益複雜的環境，基因編輯技術的進步、繁殖管理和模型表徵的改進以及複雜的重複性標準都會影響決策。隨著研究機構、製藥公司和服務供應商不斷調整，明確模型選擇、營運彈性和合規性對於維持轉化研究流程至關重要。

基因編輯、以福利為中心的管治和數位整合如何改變模型開發、檢驗方法和合作研究框架？

生物醫學研究領域正在發生一場突破性的變革，重塑著動物模型的發展、檢驗和應用方式。精準基因編輯技術的進步，特別是基於CRISPR的技術，正在加速建立高度特異性的基因修飾模型，這些模型能夠更真實地模擬人類疾病的生物學過程，從而改變模型選擇和實驗設計的標準。同時，表現型表徵和體內成像技術的進步正在提升縱向研究能力，並減少獲得可靠終點所需的動物數量，進而影響資源分配和研究進度安排。

2025 年美國貿易措施變化對臨床前供應鏈、採購韌性和跨境合作準備的影響。

美國預計2025年推出的政策干預措施和關稅調整，將為臨床前供應鏈和跨國合作帶來新的考量。影響特殊生物材料、客製化試劑和設備進出口的貿易措施，可能會影響採購前置作業時間和供應商選擇。因此，依賴國際供應商提供基因改造菌株、種畜或特殊耗材的機構，可能需要調整籌資策略，以減輕進口合規審查加強和潛在成本重新分配對其營運的影響。

實用的細分情報揭示了物種選擇、模型建構、應用領域和最終用戶概況如何產生不同的營運和科學優先事項。

細分洞察揭示了不同的動物物種、模型配置、應用領域和最終用戶如何塑造臨床前生態系統中不同的需求和策略重點。在物種層面，可區分非囓齒類動物和囓齒類動物。非囓齒類動物包括犬、非人靈長類動物和兔等物種，而囓齒類動物則包括倉鼠、豚鼠、小鼠和大鼠。這種生物多樣性導致了法律規範、飼養要求和轉化應用的差異。因此，物種選擇決策越來越依賴生理有效性和操作性考量（例如繁殖週期、飼養空間和動物福利通訊協定）之間的平衡。

區域分析揭示了美洲、歐洲、中東和非洲以及亞太地區如何影響採購、合規和合作研究策略。

區域趨勢影響著各組織在關鍵區域內動物模型採購、監管合規和合作研究策略的做法。美洲仍然是治療方法創新和合約研究的中心，學術機構和商業贊助商之間緊密的網路推動著對成熟模型和專業服務的需求。這種能力的集中支撐著強大的轉化研究項目，同時也加劇了對人才、基礎設施和實驗室空間的競爭，從而促進了戰略夥伴關係和資源共用模式的建立，以最佳化研究效率。

為那些透過在服務交付中實現專業化、資料整合和監管合規來推動競爭差異化的公司提供策略行動和夥伴關係模式。

動物模型生態系統中的關鍵企業行動體現了圍繞專業化、垂直整合和協作服務交付的策略重點。主要企業正投資於高保真基因工程技術和強大的育種項目，以提供差異化的模型產品組合；與此同時，許多服務公司正在拓展其分析和生物資訊層面，以提供動物生產以外的增值服務。這種將技術服務與更深入的數據解讀相結合的趨勢旨在彌合轉化醫學鴻溝，並為申辦方提供來自臨床前計畫的更具可操作性的見解。

為研究領導者提供切實可行、優先排序和具有策略意義的建議，以加快轉化成果的實現，同時提高模型準確性、加強供應鏈並增強福利合規性。

產業領導者應積極整合科學研究投入、供應鏈韌性和強化管治，以最大限度地掌握現有機會並降低新興風險。首先，整合先進的基因修飾建模能力（特別是基於 CRISPR 的平台和全面的表現型分析工作流程）能夠提高目標有效性，並降低下游轉化研究的不確定性。同時，各組織應制定模型表徵標準，並建立跨職能審查流程，以確保研究結果的可重複性和科學證據的有效性。

結合專家訪談、系統性文獻整合和迭代檢驗的穩健的多源調查方法，確保了有效且可操作的見解。

本分析的調查方法採用多層次策略，將初步質性研究結果與結構化的二次檢驗結合。初步研究內容包括諮詢各領域專家，涵蓋臨床前研究、獸醫學和監管事務等，以捕捉細微的營運實際情況和新興科學趨勢。除訪談外，還對同行評審文獻、技術指導文件和認證標準進行了系統性回顧，以闡明技術進步和動物福利實踐的背景。

一項決定性的整合凸顯了整合科學精確性、道德管治和供應鏈韌性的必要性，以維持轉化研究的成功。

總之，動物模型領域正進入一個深化專業知識、加強倫理課責、調整營運模式的階段。科學進步，特別是基因編輯和表現型表徵方面的進步，正在提高模型轉化應用的準確性，同時監管機構和相關人員也在提高動物福利和可重複性方面的標準。這些並行發展要求各機構謹慎選擇模型，提高供應鏈的靈活性，並投資於數據和管治基礎設施，以支持可靠的轉化研究結果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物模型市場：依動物類型分類

  • 不囓齒類動物
    • 狗
    • 非人靈長類動物
    • 兔子
  • 囓齒動物
    • 倉鼠和天竺鼠
    • 老鼠
    • 鼠

第9章：依模型類型分類的動物模型市場

  • 疾病模型
  • 基因改造模型
    • CRISPR模型
    • 敲入式模型
    • 淘汰賽模特兒
    • 基因改造模型
  • 藥理學模型
  • 手術模型

第10章：動物模型市場：依應用領域分類

  • ADME 和 PK 測試
  • 疾病調查
  • 藥物發現與開發
  • 毒性評估

第11章：動物模型市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究機構
  • 醫院和診斷檢測機構
  • 製藥和生物技術公司

第12章 動物模型市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：動物模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 動物模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國動物模型市場

第16章：中國動物模型市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurora BioSolutions
  • Biocytogen
  • Charles River Laboratories International Inc.
  • Crown Bioscience Inc.
  • Cyagen Biosciences Inc.
  • Envigo RMS LLC
  • Genoway
  • Hera BioLabs
  • ingenious targeting laboratory
  • Inotiv
  • Janvier Labs
  • Mirimus Inc.
  • Ozgene Pty Ltd
  • PhoenixBio Co. Ltd.
  • PolyGene AG
  • Taconic Biosciences Inc.
  • The Jackson Laboratory
  • Transgenic Inc.
Product Code: MRR-5D693B46BD18

The Animal Model Market was valued at USD 3.42 billion in 2025 and is projected to grow to USD 3.68 billion in 2026, with a CAGR of 8.27%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.42 billion
Estimated Year [2026] USD 3.68 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 8.27%

A comprehensive introduction outlining how scientific progress, ethical imperatives, and regulatory expectations converge to redefine preclinical animal model strategies

The contemporary animal model landscape sits at the intersection of rapid scientific innovation, stringent ethical expectations, and evolving regulatory oversight. Preclinical investigators and organizational leaders must navigate an increasingly complex environment where advances in gene editing, improvements in husbandry and model characterization, and heightened reproducibility standards collectively influence decision-making. As research institutions, pharmaceutical developers, and service providers adapt, the demand for clarity around model selection, operational resilience, and compliance has become central to sustaining translational pipelines.

Across this environment, stakeholders are placing greater emphasis on validated disease models and genetically engineered systems to increase translational relevance while simultaneously responding to external pressures to refine animal use and enhance welfare. This dynamic requires a nuanced understanding of model capabilities and limitations, as well as strategies for integrating alternative technologies where appropriate. Consequently, the ability to align scientific objectives with operational structures, vendor ecosystems, and regulatory expectations is now a critical determinant of project success and ethical stewardship.

How gene editing, welfare-driven governance, and digital integration are jointly transforming model development, validation practices, and collaborative research frameworks

Significant transformative shifts are reshaping how animal models are developed, validated, and deployed across biomedical research. Advances in precision gene editing, particularly CRISPR-based approaches, are accelerating the creation of highly specific genetically engineered models that better recapitulate human disease biology, thereby changing the calculus for model selection and experimental design. At the same time, improvements in phenotype characterization and in vivo imaging are enhancing longitudinal study capabilities and reducing the number of animals required for robust endpoints, which in turn affects resource allocation and study timelines.

Concurrently, ethical and regulatory landscapes are exerting stronger influence over experimental practice. Institutions and sponsors are strengthening governance frameworks to align with international 3Rs principles, resulting in more rigorous welfare monitoring and justification for animal use. In response, service providers and internal teams are increasingly investing in welfare-positive housing, enrichment programs, and staff training to meet both ethical expectations and scientific quality goals. In parallel, digital transformation and data integration-encompassing laboratory information management systems, standardized metadata practices, and machine learning-enabled analytics-are improving reproducibility and enabling more rapid cross-study comparisons. These combined shifts are driving a migration toward collaborative networks of specialized providers, centralized model repositories, and multidisciplinary teams that can deliver higher-confidence translational outputs.

Implications of evolving US trade measures for preclinical supply chains, procurement resilience, and cross-border collaboration preparedness in 2025

Policy interventions and tariff adjustments in the United States projected for 2025 are introducing new considerations for preclinical supply chains and cross-border collaborations. Trade measures that affect the import and export of specialized biological materials, custom reagents, and equipment can influence procurement lead times and vendor selection decisions. As a result, organizations that rely on international suppliers for genetically engineered lines, breeding stock, or specialized consumables may need to reassess sourcing strategies to mitigate the operational impact of elevated import compliance scrutiny and potential cost reallocation.

In practical terms, these trade dynamics are prompting greater attention to supplier diversification, onshoring of critical production capabilities, and regionalization of supply chains where feasible. Organizations are emphasizing contractual protections, enhanced inventory planning, and multi-supplier qualification to ensure continuity of studies and reduce exposure to policy-driven disruptions. Moreover, the tariffs dialogue is catalyzing conversations between industry stakeholders and regulatory authorities about harmonizing standards for material transfer, quarantine, and documentation to minimize administrative friction. Ultimately, the implication for research programs is a need to integrate trade policy risk into project timelines and procurement governance so that scientific objectives remain resilient in the face of shifting cross-border rules.

Actionable segmentation intelligence revealing how species selection, model construction, application focus, and end-user profiles create differentiated operational and scientific priorities

Segmentation insights reveal how distinct animal types, model constructs, application areas, and end users shape heterogeneous demands and strategic priorities across the preclinical ecosystem. The animal type dimension differentiates Nonrodents and Rodents, where Nonrodents encompass species such as Dogs, Nonhuman Primates, and Rabbits, and Rodents include Hamsters & Guinea Pigs, Mice, and Rats; this biological diversity drives variation in regulatory oversight, housing requirements, and translational applicability. Therefore, decisions about species selection are increasingly informed by the balance between physiological relevance and operational considerations such as breeding cycles, housing footprint, and welfare protocols.

Model type granularity further layers complexity: Disease Models, Genetically Engineered Models, Pharmacological Models, and Surgical Models each serve distinct experimental purposes. Within genetically engineered approaches, subdivisions such as CRISPR Models, Knock-In Models, Knockout Models, and Transgenic Models differ in their technical construction and applicability for target validation, mechanistic studies, and therapeutic testing. These differences influence not only experimental design but also validation pathways and reproducibility expectations, leading organizations to develop tailored standard operating procedures and characterization pipelines for each model class.

Applications span ADME & PK Studies, Disease Research, Drug Discovery & Development, and Toxicology Assessment, and each application imposes unique fidelity requirements, endpoint selection, and data provenance needs. For instance, ADME and pharmacokinetic investigations prioritize controlled physiology and precise sampling, whereas disease research may require complex phenotyping and longitudinal outcome measures. As a result, operational investments in assay platforms, imaging modalities, and bioanalytical capacity are frequently aligned to the dominant application portfolio of an organization.

End users range from Academic & Research Institutes to Contract Research Organizations, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies, each bringing different procurement behaviors, regulatory responsibilities, and timelines. Academic labs often prioritize exploratory flexibility and open science practices, while contract research organizations focus on scalable, validated workflows that meet sponsor requirements. Clinical laboratories and health systems integrate preclinical insights into translational pathways and diagnostic development, and industry partners require robust model justification to support regulatory submissions. Recognizing these segmentation-driven differences enables stakeholders to align model selection, vendor partnerships, and governance frameworks with the specific needs of their primary end-user constituencies.

Regional analysis highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each influence sourcing, compliance, and collaborative research strategies

Regional dynamics are shaping how organizations approach animal model sourcing, regulatory compliance, and collaboration strategies across key geographies. The Americas continue to be a hub for therapeutic innovation and contract research activity, with dense networks of academic institutions and commercial sponsors that drive demand for characterized models and specialized services. This concentration of capability supports robust translational programs, yet it also elevates competition for talent, infrastructure, and laboratory space, encouraging strategic alliances and shared-resource models to optimize throughput.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and ethical norms that influence model development and cross-border exchanges. Many jurisdictions in this region emphasize stringent welfare standards and harmonized oversight, which in turn shape vendor certification practices and study design expectations. Additionally, collaborative pan-regional consortia and public-private partnerships play a notable role in pooling resources for large-scale preclinical initiatives and in advancing standardized model validation criteria.

Asia-Pacific has emerged as a dynamic region for both service provision and model innovation, with rapid investment in gene editing capacity, breeding infrastructure, and contract research capabilities. Diverse regulatory approaches across countries create opportunities for regional specialization, while increasing local scientific expertise is fostering indigenous model development and translational research programs. Together, these regional patterns highlight the importance of tailoring sourcing strategies, compliance roadmaps, and partnership approaches to the specific risks and advantages present within each geography.

Strategic company behaviors and partnership models that drive competitive differentiation through specialization, data integration, and regulatory-aligned service offerings

Key company behaviors in the animal model ecosystem reflect strategic prioritization around specialization, vertical integration, and collaborative service delivery. Leading providers are investing in high-fidelity genetically engineered capabilities and robust breeding programs to offer differentiated model portfolios, while many service firms are expanding their analytics and bioinformatics layers to add value beyond animal production. This trend toward bundling technical services with deeper data interpretation aims to reduce translational gaps and to provide sponsors with more actionable insights from preclinical programs.

Another notable direction is the consolidation of capabilities through partnerships and alliances, enabling organizations to combine operational strengths-such as vivarium management, regenerative medicine expertise, or in vivo imaging-into comprehensive service offerings. At the same time, some providers are pursuing modular, outsourced arrangements that allow sponsors to access specific competencies without committing to full-scale integration. Across these strategies, investment in regulatory intelligence, quality management systems, and welfare accreditation is common, as customers increasingly demand demonstrable standards and traceability across the supply chain. These company-level choices influence competitive positioning, client retention, and the evolution of service-level expectations across the sector.

Practical and prioritized strategic recommendations for research leaders to enhance model fidelity, fortify supply chains, and elevate welfare compliance while accelerating translational outcomes

Industry leaders should adopt a proactive mix of scientific investment, supply chain resilience, and governance enhancements to capitalize on current opportunities and mitigate emerging risks. First, embedding advanced genetically engineered model capabilities-especially CRISPR-enabled platforms and comprehensive phenotyping workflows-will improve target validation and reduce downstream translational uncertainty. Complementing this, organizations should formalize model characterization standards and establish cross-functional review processes that ensure reproducibility and defendable scientific rationale.

Second, supply chain strategies must evolve to reduce exposure to trade policy shifts and supply interruptions. This involves diversifying vendor relationships, qualifying regional suppliers, and developing contingency inventories for mission-critical materials. In addition, investing in localized breeding capacity or regional partnerships can shorten lead times and provide operational buffers during periods of commerce volatility. Third, companies should elevate welfare and compliance governance by integrating enhanced monitoring technologies, independent audits, and staff competency programs that align with evolving ethical expectations and regulatory scrutiny.

Finally, leaders should leverage data science and digital platforms to achieve higher experimental efficiency. Standardizing metadata capture, adopting interoperable laboratory systems, and deploying machine learning for endpoint prediction will increase reproducibility and support faster decision cycles. Combined, these actions enhance scientific credibility, operational stability, and stakeholder trust, positioning organizations to sustain translational momentum while remaining responsive to policy and ethical imperatives.

Robust multi-source research methodology combining expert consultations, systematic literature synthesis, and iterative validation to ensure defensible and actionable insights

The research methodology underpinning this analysis leverages a layered approach that synthesizes primary qualitative insights with structured secondary validation. Primary inputs include consultations with subject-matter experts across preclinical research, veterinary sciences, and regulatory affairs to capture nuanced operational realities and emerging scientific trends. These interviews were supplemented by a systematic review of peer-reviewed literature, technical guidance documents, and recognized standards to contextualize technological advances and welfare practices.

Data triangulation ensured robustness by cross-referencing expert perspectives with publicly available technical reports and documented policy changes. Wherever applicable, methodological transparency was maintained through clear documentation of inclusion criteria, definitions for model classes, and the provenance of technical assertions. Ethical considerations guided the process throughout, with respect for data privacy and professional confidentiality in all expert engagements. This multi-source, iterative approach supports a defensible interpretation of sector dynamics and yields insights tailored to decision-makers requiring both operational guidance and scientific credibility.

A conclusive synthesis emphasizing the need to integrate scientific precision, ethical governance, and supply chain resilience to sustain translational success

In conclusion, the animal model landscape is entering a period of refined specialization, heightened ethical accountability, and operational recalibration. Scientific advances-especially in gene editing and phenotype characterization-are improving the translational precision of models, while at the same time regulators and stakeholders are raising the bar for welfare and reproducibility. These concurrent forces require organizations to be deliberate in model selection, to strengthen supply chain agility, and to invest in data and governance infrastructures that support reliable translational outcomes.

Looking forward, success will depend on the ability to integrate technological capabilities with responsible stewardship and pragmatic operational planning. Organizations that proactively align their scientific agendas with resilient procurement practices and transparent welfare governance will be better positioned to deliver high-quality preclinical evidence and to respond to policy or market shifts with agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Market, by Animal Type

  • 8.1. Nonrodents
    • 8.1.1. Dogs
    • 8.1.2. Nonhuman Primates
    • 8.1.3. Rabbits
  • 8.2. Rodents
    • 8.2.1. Hamsters & Guinea Pigs
    • 8.2.2. Mice
    • 8.2.3. Rats

9. Animal Model Market, by Model Type

  • 9.1. Disease Models
  • 9.2. Genetically Engineered Models
    • 9.2.1. CRISPR Models
    • 9.2.2. Knock-In Models
    • 9.2.3. Knockout Models
    • 9.2.4. Transgenic Models
  • 9.3. Pharmacological Models
  • 9.4. Surgical Models

10. Animal Model Market, by Application

  • 10.1. ADME & PK Studies
  • 10.2. Disease Research
  • 10.3. Drug Discovery & Development
  • 10.4. Toxicology Assessment

11. Animal Model Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Animal Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Model Market

16. China Animal Model Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aurora BioSolutions
  • 17.6. Biocytogen
  • 17.7. Charles River Laboratories International Inc.
  • 17.8. Crown Bioscience Inc.
  • 17.9. Cyagen Biosciences Inc.
  • 17.10. Envigo RMS LLC
  • 17.11. Genoway
  • 17.12. Hera BioLabs
  • 17.13. ingenious targeting laboratory
  • 17.14. Inotiv
  • 17.15. Janvier Labs
  • 17.16. Mirimus Inc.
  • 17.17. Ozgene Pty Ltd
  • 17.18. PhoenixBio Co. Ltd.
  • 17.19. PolyGene AG
  • 17.20. Taconic Biosciences Inc.
  • 17.21. The Jackson Laboratory
  • 17.22. Transgenic Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)